
Friday, April 03, 2020 10:56:56 AM
6:08 am ET April 3, 2020 (Dow Jones) Print
By Colin Kellaher
Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.
The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.
Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.
Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 03, 2020 06:08 ET (10:08 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
New York Yankees and Duke Basketball
Recent ZNTL News
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/02/2025 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/02/2025 10:02:38 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/14/2025 08:15:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:13:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:09:35 PM
- Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress • GlobeNewswire Inc. • 05/14/2025 08:05:00 PM
- Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/01/2025 09:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2025 08:14:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2025 08:09:53 PM
- Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC • GlobeNewswire Inc. • 04/28/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2025 10:02:15 AM
- Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting • GlobeNewswire Inc. • 04/23/2025 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/07/2025 04:15:13 AM
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/01/2025 09:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2025 08:19:53 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/26/2025 08:18:26 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2025 08:11:19 PM
- Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates • GlobeNewswire Inc. • 03/26/2025 08:05:00 PM
- Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 • GlobeNewswire Inc. • 03/25/2025 08:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2025 10:13:38 AM
- Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer • GlobeNewswire Inc. • 03/15/2025 03:25:00 PM
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/03/2025 10:00:00 PM
- Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer • GlobeNewswire Inc. • 03/03/2025 01:00:00 PM
- Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/24/2025 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2025 10:00:31 PM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM
ECGI Holdings Invests in AI-Powered Fantasy Sports Startup Payday Fantasy • ECGI • Jun 10, 2025 8:30 AM
Avant Technologies Signs Letter of Intent for a Business Combination • AVAI • Jun 10, 2025 8:00 AM
NEXT10, Inc. Announces Acquisition of Torreon Group, Inc. • NXTN • Jun 9, 2025 8:42 AM
Maybacks Global Entertainment, LLC and Plex Sign Global Licensing and Distribution Agreement • AHRO • Jun 6, 2025 8:30 AM
Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership • BLOZF • Jun 5, 2025 8:54 AM